Skip to main content
. 2011;13(1):20–33.

Figure 2.

Figure 2

Trial results comparing placebo and three dosing regimens of terazosin in men with benign prostatic hyperplasia. The effects of terazosin on (A) American Urological Association symptom score and (B) peak urinary flow rate were found to be dose dependent. Reproduced with permission from Lepor H et al, J Urol. 1992;148:1467–1474.5